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Abstract: Introduction: Gastric cancer (GC) is still a major health problem due to the majority of patients present with 
advanced disease. This considerably reduces the possibility of curative treatment. A critical decision in the treatment of 
GC is related to staging, which is mainly assessed by the use of the TNM classification. There are other factors that can 
influence in the prognosis during the preoperative period: pathological type, degree of differentiation or tumor markers 
level. The most commonly used tumor markers (TM) in GC are CEA and CA 19.9. The aim of the present study is to 
analyze the relationship between CEA and CA 19.9 markers with certain characteristics of the patients and tumors and 
to evaluate the utility of these TM determined at the time of diagnosis as prognostic factors. 
Material and methods: A prospective collection of the data of all pacients operated by GC at our centre. A total of 501 
cases were diagnosed. Mean age was 68.2 years. We analyzed age, sex, tumor location, clinical stage, tumor markers 
determined in the preoperative period, the use of perioperative chemotherapy and response to chemotherapy, the 
pathological characteristics and disease follow-up.  
Results: At the time of diagnosis 23,3 % of the patients presented high values of CEA, 32,6 % presented high values of 
CA 19.9 and 14,1% presented with both elevated markers. Patients who were diagnosed at an advanced stage and 
presented high levels of CEA or CA 19.9 or both TM had worse survival compared to those with normal values.  
Conclusion: the presence of an elevated serum level of tumor markers is related to advanced tumor stage and worse 
prognosis in terms of overall survival.  
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INTRODUCTION 
Gastric cancer (GC) continues to be a serious 
health problem despite a decrease in its incidence in 
recent years. In the West, most cases occur in 
advanced stages, which reduces the possibility of 
curative treatment. This becomes the main reason for 
its poor prognosis. 
Surgery remains the only curative treatment in early 
stages. In advanced stages, the treatment requires the 
use of perioperative chemotherapy. There are different 
chemotherapy regimens that have been proven to be 
effective and are being used in Japan, Europe and the 
United States [1-3]. The first requirement to plan an 
appropriate treatment of gastric cancer is to perform a 
correct staging [4]. For this it is essential to establish a 
stage according to the TNM classification basically by 
using imaging techniques (CT scan, ultrasound scan, 
endoscopic ultrasonography, MRI and/or PET). Each of 
these techniques has a different sensitivity for each of 
the factors of the TNM classification (T factor, N factor 
or M factor). There are characteristics, either the tumor  
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or the patient, that could influence as prognostic factors 
according to some authors, and therefore could also 
influence in the choice of preoperative treatment [5, 6], 
such as age, sex, tumor location and size, tumor 
differentiation grade, Lauren classification type, 
vascular, neural or lymphatic invasion.  
Liquid biopsy is a technique that has been recently 
introduced into the clinical practice. This analyzes a 
blood sample to determine the presence of tumor cells 
detached from the primary tumor and performs a 
genetic analysis of the same. It allows us to analyze 
the DNA of the tumor cells and to determine the 
presence of mutations in genes involved in the tumor 
growth	   such as k-RAS, PIK3CA and BRAF. This new 
technology can become an important tool at the time of 
diagnosis and can be decisive for deciding the 
treatment using effective agents against the cells that 
present the mutation [7, 8]. 
Tumor markers (TM) are circulating substances that 
are present in the blood or in other bodily fluids. They 
are usually produced by the cancer cells or by other 
tissues that are induced by the tumor. They can be 
used for screening purpose, for early diagnosis or for 
establishing a prognosis. Also variations in blood levels 
during follow-up may indicate a relapse. In addition 
variations after neoadjuvant chemotherapy allow us to 
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evaluate the tumor response. In this way the 
persistence of elevated values after surgery may 
indicate the presence of residual tumor cells [9-12].  
There is no specific TM for GC. The most commonly 
used are CEA and CA 19-9. It has been reported in the 
literature that elevated levels of CEA are correlated 
with depth of tumor invasion and the presence of 
distant metastases, whereas elevated levels of CA 19.9 
are related to nodal involvement [13-15]. 
The objective of this study is to analyze the 
relationship between CEA and CA 19.9 levels with 
certain characteristics of the patient and the tumor, and 
to evaluate the usefulness of these determinations at 
the time of diagnosis as prognostic factors. 
MATERIAL AND METHODS 
Since 1994, the data of all patients operated by GC 
at the Hospital Clínico Universitario of Valencia have 
been collected prospectively. 501 cases were included 
(311 men and 190 women) with a mean age of 68.2 
years. The diagnosis of gastric cancer was carried out 
by means of an endoscopic biopsy. Staging was 
performed using the CT scan. MRI or PET scan were 
only used in those cases where the CT did not provide 
enough information. Since 2007 an endoscopic 
ultrasonography was also performed for a better 
evaluation of the T and N factor. Levels of CEA and CA 
19-9 were determined preoperatively. Patients were 
classified into two groups for each of the markers 
according to the value obtained (higher or not for the 
limit established by the manufacturer). Also patients 
who presented both markers elevated were divided into 
two groups according to the same criteria described 
above. 
TNM classification (6th ed.) was used to determine 
the clinical stage [16]. Those cases with T ≥ 3 and / or 
N+ stage were treated by the administration of 
chemotherapy (ChT) according to the Cunningham 
scheme/model (2). Patients received three preopera- 
tive chemotherapy cycles. A re-assessment of the 
stage was performed two weeks after the last 
preoperative chemotherapy cycle was administered by 
means of CT scan, and classified as follow: (1) 
complete regression; (2) partial regression; (3) stable 
disease/no response; and (4) progressive disease. 
Four to six weeks after the end of preoperative ChT the 
patients were operated. Depending on the patient's 
condition, three additional cycles of chemotherapy	  were 
administered postoperatively. 
The follow-up was carried out by means of clinical 
evaluation, laboratory tests and CT scan every six 
months during the first two years, and every 12 months 
from the third year. In case of partial gastrectomy an 
annual endoscopy was performed for the first two years 
or if symptoms were present. Tumor growth in the 
anastomosis, or in locoregional lymph nodes or the 
appearance of carcinomatosis were defined as local 
recurrence, while distant relapse was defined as tumor 
growth in the liver or any other extraperitoneal organ.  
Collected data were: age, sex, tumor location, 
clinical stage, tumor markers determined in the 
preoperative period, perioperative ChT, response to 
ChT treatment, pathological characteristics (vascular, 
neural or lymphatic invasion, presence of signet ring 
cells, differentiation grade, Lauren type classification, 
pathological stage) and disease follow-up (develop- 
ment of recurrence and overall survival). Statistical 
analysis was performed using the chi-square test for 
the qualitative variables and the Mann-Whitney U test 
for the quantitative ones. Survival analysis was 
performed using the Kaplan-Meier and the log-rank 
tests. The Cox regression test was performed for the 
identification of the variables that could influence on 
relapse and survival. A p-value of less than 0.05 was 
established as significant. 
RESULTS 
 501 cases were finally included (311 men and 190 
women) with a mean age of 68 years. Table 1 shows 
the characteristics of the patients, tumor location, 
clinical stage, administration of ChT, response to ChT 
and preoperative values of the tumor markers. There 
were 104 cases with elevated CEA (23.3%), 105 cases 
with elevated CA 19.9 (32.6%) and 45 cases with both 
markers elevated (14.1%). 
Table 2 shows the pathological characteristics and 
the evolution of the patients (relapse and overall 
survival). 
The presence of elevated levels of CEA was related 
to the male sex and tumor stage (higher CEA levels 
were found in both clinical and pathological advanced 
stages) (Table 3). 
The presence of elevated CA 19.9 was related to 
the presence of neural infiltration and clinical / 
pathological stage (Table 3). 
When the relapse analysis was performed, no 
differences were found between those cases with 
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elevated CEA and those with elevated CA 19.9. There 
were also no differences in the presence of relapses in 
the patients with both elevated TM. 
Table 1: Patient's Age, Gender, Tumor Location, Clinical 
Stage and Tumor Markers 
AGE 68.25 ±12 (22-95) 
GENDER 
 MALE 
 FEMALE 
 
311 (62.1%) 
190 (37.9%) 
TUMOR LOCATION  
 UPPER STOMACH 
 MIDDLE STOMACH 
 LOWER STOMACH 
 WHOLE (stump, linitis) 
 
78 (15.6%) 
148 (29.5%) 
231 (46.1%) 
44 (8.8%) 
CLINICAL STAGE 
 Ia 
 Ib 
 II 
 IIIa 
 IIIb 
 IV 
 
20 (4.8%) 
55 (12.9%) 
141 (33.2%) 
123 (28.9%) 
28 (6.6%) 
58 (13.6) 
CEA ELEVATED 
 YES 
 NO 
 
104 (23.3%) 
342 (76.7%) 
Ca 19.9 ELEVATED 
 YES 
 NO 
 
105 (32.6%) 
217 (67.4%) 
CEA & CA 19.9 ELEVATED 
 YES 
 NO 
 
45 (14.1%) 
274 (85.9%) 
DIFFERENTIATION 
 WELL 
 MODERATE 
 POOR 
 
36 (11.9%) 
150 (49.5%) 
117 (38.6%) 
LAUREN 
 INTESTINAL TYPE 
 DIFUSSE TYPE 
 MIXED TYPE 
 
203 (50%) 
164 (40.4%) 
39 (9.6%) 
SIGNET RING CELLS 
 POSITIVE 
 NEGATIVE 
 
172 (40.7%) 
251 (59.3%) 
VASCULAR INVASION 
 POSITIVE 
 NEGATIVE 
 
133 (53.8%) 
114 (46.2%) 
LYMPHATIC INVASION 
 POSITIVE 
 NEGATIVE 
 
170 (63.9%) 
96 (36.1%) 
NEURAL INVASION 
 POSITIVE 
 NEGATIVE 
 
136 (53.8%) 
117 (46.2%) 
PATHOLOGICAL STAGE 
 COMPLETE RESPONSE 
 Ia 
 Ib 
 II 
 IIIa 
 IIIb 
 IV 
 
10 (2%) 
72 (14.2%) 
46 (9.2%) 
68 (13.6%) 
91 (18.2%) 
90 (18%) 
124 (24.8%) 
RELAPSE 
 YES 
 NO 
 
135 (26.9%) 
366 (73.1%) 
SITE OF RELAPSE 
 LOCAL OR LOCOREGIONAL 
 DISTANT 
 BOTH 
 
89 (65.9%) 
37 (27.4%) 
9 (6.7%) 
DEATH BY DISEASE 
 YES 
 NO 
 
215 (42.9%) 
286 (57.1%) 
 
However patients with elevation of CEA, CA 19.9 
(Figure 1 and 2) or both (Figure 3) presented worse 
overall survival. 
The multivariate analysis showed that among all 
factors that could influence on the overall survival, only 
the presence of both elevated TM (p = 0.012, HR 2.518 
CI 95% 1.225-5.174) and the pathological stage (P = 
0.004, HR 0.149, 95% CI 0.041-0.548) were significant. 
DISCUSSION 
Tumor markers have little value for the diagnosis of 
tumors because of their low sensitivity and the 
existence of non-tumoral diseases that can increase 
their value. Thus CEA level can be found increased in 
cases of inflammatory bowel disease, pancreatitis, 
cirrhosis, COPD or smoker patients; CA 19.9 level can 
be found elevated in pancreatitis or cholestasis 
syndrome [17]. Both markers have a lack of specificity 
for the diagnosis of gastric cancer. In this way, CEA 
can be found elevated in a wide range of tumors such 
as colorectal, gastric, pancreas, breast, lung or 
medullary thyroid cancer. Likewise, CA 19.9 may be 
elevated in pancreatic, colorectal, gastric and hepatic 
tumors [18]. TM may be useful to establish a prognosis 
at the time of diagnosis [17], to evaluate the outcome of 
preoperative chemotherapy and surgical treatment  
[19-21], and to suspect the occurrence of relapses 
during follow-up. 
In our study, we found an elevation of CEA in 23% 
of cases and CA 19.9 in 32.6% which are quite similar 
to those described in the literature [9, 22, 23]. Both 
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were found jointly elevated in the 14.1% of cases in our 
series. A relationship has been described between TM 
elevation and certain patient and tumor characteristics, 
although not all authors agree on which features are 
related. In our series CEA elevation is associated with 
males and with advanced tumor stages, especially in 
those cases with metastasis. This agrees with the 
found described by Zhang et al. [13] and Gaspar et al. 
[24]. Likewise we found that the increase of CA 19.9 is 
related to a more advanced stage and the presence of 
positive lymph nodes in the pathological study [14]. The 
presence of both elevated TMs is related to more 
advanced clinical and pathological stages as has also 
been described by Li et al. [25]. Perhaps this could be 
the reason why the presence of elevated TM is related 
to worse survival. 
Table 3: Factors Related to Elevation of Tumor Markers 
Global comparisons 
 Chi-cuadrado gl Sig. 
Log Rank (Mantel-Cox) 7,337 1 0,007 
Evidence of equality of survival distributions for different levels of 
CEA. 
 
The presence of elevated TM in the preoperative 
period may be important for the diagnosis of advanced 
stages that may be difficult to evaluate by imaging tests 
such as peritoneal dissemination. These findings may 
lead to the use of more aggressive diagnostic methods 
such as laparoscopy, suggest changes in the initial 
therapeutic approach, or even indicate preoperative 
treatment with chemotherapy [13, 15]. Although there 
are no prospective studies that determine the clinical 
utility of TM, there are authors who suggest that the 
joint elevation of both TM may be helpful in GC staging 
before surgery or chemotherapy [9, 25, 26]. 
 
Figure 1:Comparison of overall survival between groups 
according to high CEA. Log-rank test 0.007. 
It has been related the presence of elevated tumoral 
markers to a worse prognosis in different types of 
cancer [18, 27-30]. This has been widely studied in 
cases of patients with colon cancer. In our series, the 
presence of elevated CEA is associated with worse 
overall survival which has also been reported by 
several authors [31, 32], although it is not associated 
with worse disease-free interval as Marrelli et al. have 
reported [33]. The increase in CA 19.9 is also an 
Table 2: Pathological Characteristics and Disease Evolution 
 CEA Elevated (p value) CA 19-9 Elevated (p value) Both Elevated (p value) 
Gender (male) 0.001   
Clinical stage 0.004   
Clinical M stage 0.002   
Pathological M+ stage 0.000   
Pathological stage 0.002   
Clinical N stage  0.04  
Pathological T stage  0.004  
Pathological N stage  0.002  
Pathological M stage  0.027  
Pathological stage  0.004  
Clinical N stage   0.007 
Pathological T stage   0.04 
Pathological N stage   0.03 
Pathological M stage   0.01 
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unfavorable prognostic factor in our series with worse 
overall survival. On the multivariate analysis, the jointly 
increase of both markers and the pathological stage 
are independent factors of poor prognosis.  
 
Figure 2: Comparison of overall survival in elevated CA 19.9 
cases. Log rank: 0.001. 
 
Figure 3: Comparison of overall survival in patients with both 
elevated and non-elevated TM markers. Log Rank, p = 0.004.  
These data confirm those published by Wang et al 
that demonstrate that determination of CEA, CA 19.9 
and CA 125 provides more information than the 
separate determination of each of them [34]. In our 
study, we found no differences in the analysis of the 
relapse-free interval and the presence of elevated TM, 
a fact that is consistent with the work of Huang and 
coworkers [29]. However, other authors find a 
relationship between elevated TM levels in the 
preoperative period and the relapse-free interval [35].  
CONCLUSION 
Therefore, we can conclude that the presence of 
elevation of CEA and CA 19.9 is related to the 
existence of advanced stages and with a worse 
prognosis in terms of overall survival. The determina- 
tion of both elevated TM is an independent prognostic 
factor for overall survival and may provide important 
prognostic information in the preoperative period. 
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